Chronic Spontaneous Urticaria - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Chronic Spontaneous Urticaria - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Spontaneous Urticaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chronic Spontaneous Urticaria: Overview
Urticaria (also called hives, wheals, or nettle rash) is characterized by pruritic, erythematous, and edematous wheals. Chronic Spontaneous Urticaria (CSU) is defined as hives that are present for at least or greater than 6 weeks and for the most days of the week. Chronic spontaneous urticaria is characterized by the presence of weals and angioedema. Weals can affect any site on the body and tend to be distributed widely. Chronic urticaria is diagnosed is based on a history lasting over 6 weeks of daily or episodic weals that last less than 24 hours without the presence of physical trigger factors. The international guidelines recommend limiting investigations in most patients with chronic spontaneous urticaria to differential blood count and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Medicines for the treatment of chronic spontaneous urticarial are antihistamines, omalizumab, cyclosporine, and low-dose corticosteroids.
'Chronic Spontaneous Urticaria - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Spontaneous Urticaria pipeline landscape is provided which includes the disease overview and Chronic Spontaneous Urticaria treatment guidelines. The assessment part of the report embraces, in depth Chronic Spontaneous Urticaria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Spontaneous Urticaria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Chronic Spontaneous Urticaria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Spontaneous Urticaria Emerging Drugs
Further product details are provided in the report……..
Chronic Spontaneous Urticaria: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Spontaneous Urticaria drugs segregated based on following parameters that define the scope of the report, such as:
Chronic Spontaneous Urticaria: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic Spontaneous Urticaria therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Spontaneous Urticaria drugs.
Chronic Spontaneous Urticaria Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Chronic Spontaneous Urticaria - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Spontaneous Urticaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chronic Spontaneous Urticaria: Overview
Urticaria (also called hives, wheals, or nettle rash) is characterized by pruritic, erythematous, and edematous wheals. Chronic Spontaneous Urticaria (CSU) is defined as hives that are present for at least or greater than 6 weeks and for the most days of the week. Chronic spontaneous urticaria is characterized by the presence of weals and angioedema. Weals can affect any site on the body and tend to be distributed widely. Chronic urticaria is diagnosed is based on a history lasting over 6 weeks of daily or episodic weals that last less than 24 hours without the presence of physical trigger factors. The international guidelines recommend limiting investigations in most patients with chronic spontaneous urticaria to differential blood count and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Medicines for the treatment of chronic spontaneous urticarial are antihistamines, omalizumab, cyclosporine, and low-dose corticosteroids.
'Chronic Spontaneous Urticaria - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Spontaneous Urticaria pipeline landscape is provided which includes the disease overview and Chronic Spontaneous Urticaria treatment guidelines. The assessment part of the report embraces, in depth Chronic Spontaneous Urticaria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Spontaneous Urticaria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Spontaneous Urticaria R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Spontaneous Urticaria.
This segment of the Chronic Spontaneous Urticaria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Spontaneous Urticaria Emerging Drugs
- Ligelizumab: Novartis
- Tezepelumab: Amgen
Further product details are provided in the report……..
Chronic Spontaneous Urticaria: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Spontaneous Urticaria drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chronic Spontaneous Urticaria
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Chronic Spontaneous Urticaria: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic Spontaneous Urticaria therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Spontaneous Urticaria drugs.
Chronic Spontaneous Urticaria Report Insights
- Chronic Spontaneous Urticaria Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic Spontaneous Urticaria drugs?
- How many Chronic Spontaneous Urticaria drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Spontaneous Urticaria?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Spontaneous Urticaria therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic Spontaneous Urticaria and their status?
- What are the key designations that have been granted to the emerging drugs?
- Celltrion
- Novartis
- Amgen
- Stero Biotechs
- Allakos
- Gilead Sciences
- Celldex Therapeutics
- United BioPharma
- Eden Biologics
- GI Innovation
- Astrazeneca
- Regeneron
- UCB Biopharma
- Genentech
- CT-P39
- Ligelizumab
- Tezepelumab
- Cannabidiol
- Lirentelimab
- Tirabrutinib
- CDX 0159
- UB-221
- Research programme: biosimilars
- GI-301
- Benralizumab
- Dupilumab
- UCB-8600
- Remibrutinib
- Fenebrutinib
Introduction
Executive Summary
Chronic Spontaneous Urticaria: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic Spontaneous Urticaria – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Ligelizumab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tezepelumab: Amgen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CDX-0159: Celldex Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
GI-301: GI Innovation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic Spontaneous Urticaria Key Companies
Chronic Spontaneous Urticaria Key Products
Chronic Spontaneous Urticaria- Unmet Needs
Chronic Spontaneous Urticaria- Market Drivers and Barriers
Chronic Spontaneous Urticaria- Future Perspectives and Conclusion
Chronic Spontaneous Urticaria Analyst Views
Appendix
Executive Summary
Chronic Spontaneous Urticaria: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic Spontaneous Urticaria – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Ligelizumab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tezepelumab: Amgen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CDX-0159: Celldex Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
GI-301: GI Innovation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic Spontaneous Urticaria Key Companies
Chronic Spontaneous Urticaria Key Products
Chronic Spontaneous Urticaria- Unmet Needs
Chronic Spontaneous Urticaria- Market Drivers and Barriers
Chronic Spontaneous Urticaria- Future Perspectives and Conclusion
Chronic Spontaneous Urticaria Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Chronic Spontaneous Urticaria
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Chronic Spontaneous Urticaria
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Chronic Spontaneous Urticaria
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Chronic Spontaneous Urticaria
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
